About us

Dianosic designs transformative long-acting resorbable intranasal solid-dosage forms to overcome the delivery challenges of chronic respiratory and CNS therapies

Our history

Our journey : from a clinical insight in ENT practice to a transformative intranasal drug-delivery platform built to redefine the treatment of chronic respiratory and CNS diseases.

Origin

Solutions for treating nasal cavity pathologies remain poorly developed and largely underserved. Existing options are invasive, anxiety-provoking for patients, and suffer from low compliance. Dianosic was founded in 2017 to address these unmet clinical needs, in close collaboration with the ENT department of the University Hospitals of Strasbourg and has since grown into a biotech developing a proprietary intranasal drug-delivery platform.

2026

Phase I clinical trial initiation in CAR. Co-development opportunities with Pharma partners materialize.

2025

Dianosic prepares for launch of its Phase I clinical trial in chronic allergic rhinitis (CAR). Confirmation of positive results in N2B (schizophrenia).
Dianosic Closing of a €7 million financing round.

2024

Promising initial results in N2B (schizophrenia).

2023

Dianosic raises €4.7 M to advance its DIA01-R program in chronic allergic rhinitis and kick off activities in Neuroscience (Nose-To-Brain)

2022

Fully functional prototype of DIA01-R in chronic allergic rhinitis. Promising in vivo results.

2021

Dianosic produces robust in vitro and in vivo data for its DIAXX platform (respiratory indications).
Lancement réussi de CAVI-T en Europe après la pandémie de COVID

2020

Dianosic closes a first funding round of €1.5 million.

2019

Dianosic is laureate of the prestigious i-Lab innovation program.

2018

Dianosic starts initial R&D activities for its DIAXX platform in respiratory diseases.

2017

Development of the asymmetric intranasal balloon CAVI-T, a minimally invasive solution to improve the treatment of epistaxis.

Origine

Dianosic is co-founded by Marc Augustin (President), Philippe Bastide (CEO) and Pr Christian Debry (Head of the ENT Dept at the University Hospital of Strasbourg).

Our mission and ambitions

Dianosic's commitment to enhancing respiratory care and addressing brain diseases

We collaborate and define unmet clinical needs with healthcare professionals and ultimately aim at providing disruptive solutions to the patients and the medical community.

Excellent nasal retention without compromising patient comfort and quality of life.

The administration of long-acting intranasal solid dosage forms enables the treatment of multiple respiratory diseases at low doses, delivered directly at the site of action or in its vicinity (CNS).

Addresses a major challenge in patient adherence to treatment.

For central nervous system disorders, this approach has the potential to overcome major drug-delivery barriers by leveraging the “nose-to-brain” pathway.

Solution smartly designed for you

Discover our pipeline

Our team

Qualified team with complementary profiles

Marc Augustin Chairman / Founder

Seasoned entrepreneur
>20 years of experience in Finance and International Development (Stellantis, IBM)
Member of the executive committee of the health insurancel company UNEO
Merger Acquisition / fundraising advisor (ACM partners)
Linkedin account: https://bit.ly/3EvE9u1

Philippe Bastide CEO/ Founder

> 20 years of experience in Medtech and Pharma (Pfizer, Johnson & Johnson, Livanova)
Business Unit Lead at Acclarent (ENT Division of Johnson & Johnson)
Expertise in Market Access (pricing & reimbursement), Business Development and Professional Education
Linkedin account: https://bit.ly/3sRamJv

Emilie Fournier, PhD CSO - Chief Scientific Officer

10 years' experience in medical devices and pharmaceuticals (Roche)
Expertise in quality management & regulatory affairs
Doctorate in Biology from the University of Strasbourg (CIFRE SANOFI)
Linkedin account: https://bit.ly/44RT6l2

Eric Le Goff CMC Director

14 years of experience in pharmaceutical development, generics, orphan drugs and combination products
CMC Regulatory Project Management invariuous companies (INNOTHERA, NOVARTIS, OT4B )
Expertise in product development and analytical chemistry
Linkedin account: https://bit.ly/44GfrSh

Khadija Elhabazi, PhD Quality Manager, Clinical Operations Engineer

10 years' experience in research projects (University of Strasbourg)
Expertise in in vivo studies
PhD in Pharmacology + Diploma in Clinical Research
Linkedin account: https://bit.ly/3sQRomk

Victor Moreau R&D Engineer

Healthcare engineer (Master's degree in healthcare engineering, medical devices option, Montpellier, DEDIENNE SANTÉ)
Expertise in medical device (or healthcare product) design
Specialized in biodegradable polymers and active ingredient release
Linkedin account: https://bit.ly/3LfIgOD

Pedro Costa Campos COO - Chief Operating Officer

Over 20 years' career in the healthcare industry
Solid experience in general management, operational strategy, business development, marketing and sales management at international level, across regions (Johnson & Johnson).
Linkedin account: https://bit.ly/3EvE9u1

Jean-Charles Vignole Business Intelligence & commercial development manager

Student at ESSCA business school, Master international Business
Professional experience in the Medtech world (Johnson & Johnson)
Linkedin account: https://bit.ly/3ZgllbS

Christophe Kica Finance & Accounting

>20 years experience as chartered accountant, statutory auditor and Financial lead in Medium Caps and startups (Cléry, CTG Group, TheUpScalers).
Linkedin account:
https://www.linkedin.com/in/christophe-kica-50705218/

Pr. Christian Debry ENT surgeon / Founder

ENT Surgeon, University Hospital of Strasbourg, France
Rhinology and skull base surgery expert
Co-Director of the INSERM 1121 Research Unit (“Bioengineering and biomaterial)
Co-Director of the lab for skull base surgery (IRCAD)
Board member of the French ENT Society, French College of ENT and Head & Neck Surgery and the French Association for Pediatric ENT
Founder of Protip Médical (World first implantation of an artificial larynx, 2012)
Linkedin account: https://bit.ly/3P8tcn5

Pr. Howard Levine ENT surgeon

ENT surgeon (USA)
Founding Director of the Cleveland Nasal-Sinus & Sleep Center
Past President of the American Rhinologic Society
Former Vice President of Medical Affairs at Acclarent (J&J)
Featured in the prestigious “Best Doctors in America” and “America’s Top Doctors” lists
Investigator, lecturer and co-author of ENT reference articles
Linkedin : https://www.linkedin.com/in/howard-levine-a609bb31/

Pr. Wytske Fokkens ENT surgeon

ENT surgeon at Amsterdam University Medical Centres
World renowned specialist in the field of sinus and skull base surgery
Member of the key international Scientific Societies (ERS, EPOS, ARIA, GA2LEN)
Author of more than 500 scientific articles
Linkedin : https://www.linkedin.com/in/wytske-fokkens-a3284981/

Pr. Sébastien Froelich Neurosurgeon

Neurosurgeon, Lariboisière Hospital, APHP (Paris)
President of the « Skull base » Committee of the Worldwide Federation of Neurosurgery (WFNS)
Executive member of the European Skull Base Society (ESBS)
Linkedin : https://www.linkedin.com/in/s%C3%A9bastien-froelich-746861241/

Dr. Zara Patel Associate ENT Surgeon

Director of Endoscopic Skull Base Surgery (Stanford School of Medicine)
Associate Professor of Otolaryngology – Head and Neck Surgery (Stanford School of Medicine)
Expert in advanced endoscopic sinus and skull base surgery
Member of the Board of Directors (American Rhinologic Society)
Author of ENT reference articles
Linkedin : https://www.linkedin.com/in/zarampatelmd/

Pr. Claire Hopkins ENT surgeon

Consultant ENT Surgeon at Guy’s and St Thomas’ Hospital (London)
World renowned specialist focusing on rhinology and anterior skull base surgery
Chair of the UK Rhinosinusitis Commissioning Guidance Group and the Treasurer for the European Rhinologic Society
Claire has published over 150 papers in medical journals and 20 book chapters
Linkedin : https://www.linkedin.com/in/claire-hopkins-b4211448/

Pr. Pablo Stolovitzky ENT Surgeon

Adjunct Associate Professor, Dept. of Otolaryngology, Emory University
CEO, ENT of Georgia North
General Secretary, Pan-American ORL Association
Past Director, AAO-HNS Board of Directors
International Steering Committee, AAO-HNS
President of the 2022 Pan-American Congress of Otolaryngology
Investigator and author of Otolaryngology reference articles
Linkedin : https://www.linkedin.com/in/pablo-stolovitzky-md-01794a76/

Pr. Eric Vicaut Health Technology Assessment expert

HTA expert, Statistician and clinical trials methodologist (Paris, Fernand Widal, APHP)
Former member of Marketing Authorization Commission and Medical Devices Commission (CNEDIMTS)
Founder of the Medical Devices Evaluation Center (CEDM)
Member of the Galien Awards jury
Pr. Vicaut does not receive any financial compensation for his work as scientific advisor
Linkedin : https://www.linkedin.com/in/eric-vicaut-468aa8345/

Philippe Bastide CEO/ Founder

> 20 years of experience in Medtech and Pharma (Pfizer, Johnson & Johnson, Livanova)
Business Unit Lead at Acclarent (ENT Division of Johnson & Johnson)
Expertise in Market Access (pricing & reimbursement), Business Development and Professional Education
Linkedin account: https://bit.ly/3sRamJv

Marc Augustin Chairman / Founder

Seasoned entrepreneur
>20 years of experience in Finance and International Development (Stellantis, IBM)
Member of the executive committee of the health insurancel company UNEO
Merger Acquisition / fundraising advisor (ACM partners)
LinkedIn https://www.linkedin.com/in/marcaugustin/

Alex Theodorakis President Aptar Pharma Prescription at Aptar

Alex Theodorakis is President, Aptar Pharma Prescription, he oversees global prescription pharmaceutical activities ($800M), including the Congers, Le Vaudreuil, Mumbai, and Suzhou sites. With over 25 years at Aptar, he began his career in technical support at BLM Associates (later Valois of America, now Aptar).

He subsequently held roles in sales and production across North America, worked in France at the Le Vaudreuil site, and later managed pharmaceutical and commercial operations in the United States before being appointed to his current position in 2017.
Linkedin account:
https://www.linkedin.com/in/alex-theodorakis-b07b7837/

Jérémy Paulen Director Business Development Allergy at Aptar

Jérémy Paulen is Director of Business Development for Allergy & White Spaces at Aptar Pharma. He specializes in innovation, strategic partnerships, and nasal drug-delivery technologies.

With over a decade of experience across pharma, medical devices, and consumer health, he focuses on translating advanced drug-delivery platforms into patient-centric and value-creating solutions.
Linkedin account:
https://www.linkedin.com/in/jeremypaulen/

Jean-Francois Rax Managing Partner – Head of Seed Funding at Capital Grand Est

Jean-François Rax is Partner and Head of Seed Funding, specialized in life sciences. He joined Capital Grand Est in 2014 as Life Sciences Investment Director for the seed fund Cap Innov’Est and has served as a member of the Managing Board since 2020, overseeing the seed investment department (€87M under management).

Previously, he was a collaborator at Inserm Transfert Initiative, a French seed fund dedicated to life sciences and human health.
Linkedin account:
https://www.linkedin.com/in/jean-francois-rax-0946512/

Alexandre Koressios Directeur d’Investissement at Finovam Gestion

Alexandre Koressios is an investment professional and venture capital executive. He is a Member of the Management Board at Finovam Gestion, a venture capital firm specialized in early-stage technology investments in French regions, where he leads the Grand Est office.

He began his career in audit at Deloitte before supporting entrepreneurs at Réseau Entreprendre Paris. He later joined Starquest Capital as Investment Director and participated in around thirty technology startup closings. Alexandre has invested in digital and healthcare companies and actively supports his portfolio through board participation and strategic guidance.
Linkedin account:
https://www.linkedin.com/in/alexandrekoressios/

Séverine Lacourt Global Asset Strategy Lead, Telitacicept at Vor Bio

Séverine is Head of Global Asset Strategy for telitacicept at Vor Bio. Previously, she spent over 15 years at Bristol Myers Squibb (BMS), where she held several senior commercial roles globally in hematology, biomarkers, COVID-19 monoclonal antibodies, and Zeposia, and served as Chief of Staff to CEO Giovanni Caforio.

Her international experience has led her to leadership positions in France, China, and the United States, encompassing commercial excellence, portfolio strategy, and the management of international programs. She began her career at the Boston Consulting Group before holding senior commercial roles in the pharmaceutical industry (GSK, Sanofi, J&J). She is a graduate of HEC Paris and holds an MBA from INSEAD.
Linkedin account:
https://www.linkedin.com/in/severine-lacourt-865763b/

Eric Brandt Investment Manager at Noshaq

Eric Brandt is Investment Manager at Noshaq, an institutional venture capital firm based in Wallonia, Belgium. He is active in the life sciences sector and manages a portfolio of biotech and medtech companies.

His work spans originating and structuring seed and growth financings, serving on boards, and supporting portfolio strategy. He previously consulted for life sciences start-ups and SMEs, gaining hands-on experience in operations and company building. He studied business administration at the University of Liège and furthered his education at Vlerick Business School.
Linkedin account:
https://www.linkedin.com/in/eric-brandt-6529613/

Clémentine Lombaert Analyste at Capital Grand Est

Clémentine Lombaert is an Analyst at Capital Grand Est, where she has been working since 2022 on seed-stage investments through the Cap Innov’Est fund.

She contributes to opportunity assessment, due diligence, and the strategic monitoring of portfolio companies. She holds a general engineering degree with a specialization in life sciences, completed following a final-year project in private equity.
Linkedin account:
https://www.linkedin.com/in/cl%C3%A9mentine-lombaert-/

Partners & Investors

We built a solid network of partners to fuel company's growth.

Dianosic is backed by a Corporate partner (Aptar, US, a worldwide leader in the field of intranasal drug-delivery solutions), Venture Capital firms (Noshaq, Belgium; Capital Grand Est and Finovam, France, Clery, France and AKWA, Morocco) and by Business Angels.

Beside this, Dianosic is supported by Bpifrance, Banque Populaire and Caisse d’Epargne as well as the Fondation Force (France). Other key partners are : Quest For Health, Region Grand Est, Biovalley France, Conectus and the Eurometropole.

News & Investors